Abstract Library

#4507 Biliary complications for metastatic patients with neuroendocrine tumours of the pancreatic head and their influence on survival: Is it necessary to change the current management?

Introduction: Neuroendocrine tumours of the pancreatic head (NETPH) can be associated with local complications. At the metastatic stage, surgery of the primary tumour (PT) is not a standard of care. But the biliary complications (BC) due to the untreated NETPH may complicate the management and deteriorate the prognosis.

Conference:

Presenting Author: Ujlaki G

Authors: Ujlaki G, Fernandez de Sevilla E, Moog S, Lamartina L, Hadoux J,

Keywords: neuroendocrine, pancreatic head, metastatic, biliary complications,

#3703 Impact of primary tumor resection and metastasectomy among gastroenteropancreatic neuroendocrine tumors with liver metastases only on survival

Introduction: The incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is increasing globally, and the patients are often diagnosed with synchronous liver metastases. Despite recommendations for primary tumor resection (PTR) with or without liver resection (LR) in the patients, there are conflicting data for their impact on overall survival (OS).

Conference:

Presenting Author: Chen Q

Authors: Chen Q, Li K, Rhodin K, Bartholomew A, Lidsky M,

Keywords: Gastroenteropancreatic neuroendocrine tumor, Liver metastasis, Resection, Prognosis, National Cancer Database,

#1056 Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases

Introduction: The value of surgical resection in the management of pancreatic neuroendocrine tumor (PNET) with liver metastases (LM) is still debated.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Partelli S

Authors: Partelli S, Inama M, Rinke A, Begum N, Valente R,

Keywords: surgery, metastases, NET, survival,

#816 Resection at Diagnosis of the Primary Pancreatic Neuroendocrine Tumor in Patients with Unresectable Liver Metastases. A Possible New Approach for a Multimodal Treatment

Introduction: Pancreatic neuroendocrine tumors (PNETs) present in more than 50% of cases with liver metastases as the only systemic localization. Liver metastases are unresectable in 80% of cases at diagnosis. In the context of metastatic disease, the benefit of primary tumor removal in terms of survival is controversial

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Bertani E, Chiappa A, Fazio N, Falconi M, Spada F,

Keywords: pancreatic neuroendocrine tumor, synchronous liver metastases, debulking, resection, prognostic factors, survival,

#648 Mammalian Target of Rapamycin (mTOR) Expression Analysis and Therapeutic Approach in Primitive (T) and Metastatic (M) Ileal Neuroendocrine Tumors (INT)

Introduction: mTOR signalling pathway has emerged as a promising target for well-differentiated endocrine pancreatic carcinoma therapy. Because of varying behavior, INT are usually excluded from clinical trials employing the mTOR inhibitor, RAD001.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: MILIONE M

Authors: Milione M, Pusceddu S, Buzzoni R, Damato A, Coppa J,

Keywords: mTor, midgut, carcinoid,